Pediatrix (MD) Q4 2025 earnings review
Pricing Power Saves the Quarter as Volumes Turn Negative
Pediatrix closed 2025 with a mixed Q4. While Adjusted EPS of $0.50 beat prior year ($0.51 vs $0.36 GAAP implies operational improvement, though Adj EPS was roughly flat), the underlying drivers shifted drastically. Same-unit volume, which had been a growth engine earlier in the year, reversed into negative territory (-2.7%). However, strong reimbursement tailwinds (+6.7%) fueled by collections and acuity saved the top line. The company turned a massive corner on full-year profitability, posting Net Income of $165M for FY25 vs a $99M loss in FY24.
🐂 Bull Case
Operating cash flow remains robust ($114.6M in Q4), bolstering the balance sheet to $375.2M in cash (up from $230M YoY) despite $64M in share repurchases during the quarter.
Same-unit revenue from net reimbursement grew 6.7%, driven by improved collections, higher patient acuity (neonatology), and better administrative fees. This indicates strong execution in Revenue Cycle Management (RCM).
🐻 Bear Case
Same-unit volume growth turned negative (-2.7%) after three quarters of growth. Hospital-based services (-3.3%) and NICU days (-2.0%) both contracted, signaling potential demand headwinds.
Adjusted EBITDA margin compressed sequentially from Q3 ($87M) to Q4 ($66M), driven largely by an increase in variable practice incentive compensation. Cost containment in salaries is being offset by performance bonuses.
⚖️ Verdict: ⚪
Neutral. The full-year turnaround from loss to profit is impressive, and the balance sheet is a fortress. However, the sudden reversal in patient volume (-2.7%) in Q4 is a significant operational red flag that places immense pressure on pricing to sustain growth.
Key Themes
Volume Contraction Shock
After a year of positive volume trends (+1.6% in Q1, +2.9% in Q2), Q4 saw a sharp reversal with same-unit volume falling 2.7%. Specifically, Hospital-based services dropped 3.3% and NICU days fell 2.0%. This contradicts the narrative of 'indispensable partner' stability seen in prior quarters.
Revenue Cycle Management (RCM) Execution
Pricing remains the company's primary shield. Same-unit reimbursement grew 6.7%, driven by collections and acuity. This metric has accelerated significantly from H1 2025 levels (3.5%-4.6%), validating the effectiveness of the hybrid RCM model transition completed earlier in the year.
Fortress Balance Sheet
Cash and equivalents surged to $375.2M, up 63% YoY ($229.9M in 24Q4). Net debt has decreased, and the company deployed $64M into buybacks in Q4 alone. This liquidity provides significant optionality for M&A or further returns in 2026.
Expense Friction: Incentive Compensation
While practice salaries were managed well (down slightly YoY due to dispositions), G&A expenses rose to $65.7M (vs $63.6M LY) and Adjusted EBITDA dropped sequentially. Management cited 'higher variable practice incentive compensation' as the primary drag, suggesting that revenue outperformance is coming at a higher marginal cost.
Portfolio Optimization Drag
Consolidated Net Revenue fell to $493.8M vs $502.4M LY. This decline is entirely due to non-same unit activity (practice dispositions). While this was a planned strategic move to exit low-margin businesses, it continues to create headline revenue contraction.
Restructuring Expenses Tapering
Transformational and restructuring expenses dropped significantly to $5.9M in Q4 2025 from $23.6M in Q4 2024. This signals the conclusion of the heavy lifting regarding portfolio exits and RCM transitions, cleaning up the GAAP income statement for FY26.
Other KPIs
Reversing. A massive improvement from the FY24 Net Loss of $99.1M. This was driven by the absence of last year's goodwill impairments ($150M in FY24) and improved operating performance.
Decelerating. Down from $134.8M in 24Q4, largely due to timing of payments and working capital changes, though still sufficient to fund robust buybacks and CapEx.
Reversing. This key volume metric turned negative in Q4 after growing 2.2% in Q3 and 6.0% in Q2. This tracks closely with the broader volume decline.
Guidance
Stable/Accelerating. The midpoint ($290M) implies ~5.2% growth over FY25 Actuals ($275.6M). This suggests management expects the pricing strength to outweigh volume headwinds, or for volume to stabilize. Note: Preliminary outlook.
Key Questions
Volume Reversal Drivers
Same-unit volume dropped 2.7% in Q4 after being positive all year. Was this driven by specific lost contracts, birth rate volatility, or competitive losses? Is this the new normal for 2026?
Pricing Sustainability
With volume down, the quarter was saved by a 6.7% reimbursement jump. How much of this is structural (contract rates) vs. one-time collection catch-ups or acuity spikes that may normalize?
Incentive Comp Dynamics
Variable incentive comp weighed on Q4 EBITDA despite the revenue beat. How should we model the correlation between revenue beats and incentive payouts in 2026? Is operating leverage constrained?